NuCana plc ADR logo

NuCana plc ADR (N04)

Market Closed
11 Jul, 20:00
XBER XBER
0. 04
-0.01
-15%
2.99M Market Cap
- P/E Ratio
- Div Yield
20,000 Volume
-15.75 Eps
0.05
Previous Close
Day Range
0.04 0.05
Year Range
0.04 7.9
Want to track N04 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 38 days

Summary

N04 closed Friday lower at €0.04, a decrease of 15% from Thursday's close, completing a monthly decrease of -16.67% or €0.01. Over the past 12 months, N04 stock lost -96.3%.
N04 is not paying dividends to its shareholders.
The last earnings report, released on May 14, 2025, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -0.35%, based on the last three reports. The next scheduled earnings report is due on Aug 21, 2025.
NuCana plc ADR has completed 1 stock splits, with the recent split occurring on Apr 16, 2024.
The company's stock is traded on 5 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).

N04 Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.
Baillie Gifford's Strategic Acquisition of NuCana PLC Shares

Baillie Gifford's Strategic Acquisition of NuCana PLC Shares

On September 1, 2024, Baillie Gifford (Trades, Portfolio), a prominent investment management firm, expanded its portfolio by acquiring 917,600 shares of NuCana PLC, a UK-based biopharmaceutical company. This transaction, executed at a price of $3.66 per share, marks a significant addition to Baillie Gifford (Trades, Portfolio)'s holdings, reflecting a strategic move within the biotechnology sector.

Gurufocus | 9 months ago
NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study

NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study

NCNA stock surges 151% on positive efficacy data from the mid-stage melanoma study of NUC-7738 in combination with Merck's Keytruda.

Zacks | 9 months ago

NuCana plc ADR Dividends

N04 is not paying dividends to its shareholders.

NuCana plc ADR Earnings

21 Aug 2025 (In 1 month) Date
-
Cons. EPS
-
EPS
14 May 2025 Date
-
Cons. EPS
-
EPS
18 Mar 2025 Date
-
Cons. EPS
-
EPS
16 Nov 2023 Date
-
Cons. EPS
-
EPS
15 Nov 2023 Date
-
Cons. EPS
-
EPS
N04 is not paying dividends to its shareholders.
21 Aug 2025 (In 1 month) Date
-
Cons. EPS
-
EPS
14 May 2025 Date
-
Cons. EPS
-
EPS
18 Mar 2025 Date
-
Cons. EPS
-
EPS
16 Nov 2023 Date
-
Cons. EPS
-
EPS
15 Nov 2023 Date
-
Cons. EPS
-
EPS

NuCana plc ADR (N04) FAQ

What is the stock price today?

The current price is €0.04.

On which exchange is it traded?

NuCana plc ADR is listed on NASDAQ (CM).

What is its stock symbol?

The ticker symbol is N04.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 2.99M.

When is the next earnings date?

The next earnings report will release on Aug 21, 2025.

Has NuCana plc ADR ever had a stock split?

NuCana plc ADR had 1 splits and the recent split was on Apr 16, 2024.

NuCana plc ADR Profile

Biotechnology Industry
Healthcare Sector
Hugh Stephen Griffith CEO
XBER Exchange
US67022C2052 ISIN
GB Country
20 Employees
- Last Dividend
16 Apr 2024 Last Split
28 Sep 2017 IPO Date

Overview

NuCana plc is a clinical-stage biopharmaceutical company dedicated to the development of innovative medicines for treating cancer patients. Founded in 1997 and undergoing a rebranding from NuCana BioMed Limited in August 2017, the company has its headquarters in Edinburgh, United Kingdom. NuCana leverages its proprietary ProTide technology to advance the field of cancer treatment. This technology is aimed at transforming existing chemotherapy agents and nucleoside analogs into more effective medicines, thereby addressing the limitations of traditional nucleoside analogs. Through the enhancement of these compounds, NuCana's approach is designed to produce significantly higher concentrations of anti-cancer metabolites within cancer cells. The company's commitment to improving patient outcomes has led it to establish a collaboration agreement with Cardiff ProTides Ltd for the discovery and design of potential drug candidates.

Products and Services

  • NUC-3373

    A next-generation compound derived from the nucleoside analog 5-fluorouracil, NUC-3373 is being developed to optimize the efficacy and safety profile of cancer treatment. NuCana is conducting a multifaceted clinical trial program for NUC-3373, which includes a Phase 1b/2 study in patients with metastatic colorectal cancer, a Phase 2 trial for second-line treatment of advanced colorectal cancer, and a Phase 1b/2 trial aimed at treating patients with advanced solid tumors and lung cancer. The goal of NUC-3373 development is to overcome the limitations of 5-fluorouracil and deliver enhanced concentrations of anti-cancer metabolites directly to cancer cells.

  • NUC-7738

    This ProTide transformation of 3'-deoxyadenosine represents another facet of NuCana's robust oncology pipeline. NUC-7738 is intended to provide a novel treatment option for patients with advanced solid tumors. The development of NUC-7738 is propelled by its ongoing Phase 2 study, which is part of a broader Phase 1/2 clinical trial designed to assess its efficacy and safety in a cancer care setting. Through the innovative application of ProTide technology, NUC-7738 seeks to harness the potential of nucleoside analogs in a novel way, targeting the unmet needs of patients facing advanced stages of cancer.

Contact Information

Address: 3 Lochside Way
Phone: 44 13 1357 1111